Endocrinology & Diabetes ResearchISSN: 2470-7570

Reach Us +12097300872
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Commentary, Endocrinol Diabetes Res Vol: 1 Issue: 2

Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis

Moulinath Banerjee1,2*
1Consultant Physician: Bolton NHS Foundation Trust, Minerva Road, Bolton UK BL4 0JR, United Kingdom
2Honorary Clinical Lecturer, Diabetes & Endocrine Research Group, Manchester University, Oxford Road M13 9RT, United Kingdom
Corresponding author : Dr. Moulinath Banerjee
Honorary Clinical Lecturer, Diabetes & Endocrine Research Group, Manchester University, Oxford Road M13 9RT, United Kingdom
Tel: 01204 390583
Fax: 01204 390552
E-mail: [email protected]
Received: June 26, 2015 Accepted: August 26, 2015 Published: August 30, 2015
Citation: Banerjee M (2015) Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis. Endocrinol Diabetes Res 1:2. doi:10.4172/2470-7570.1000107

Abstract

Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.

Keywords: Sodium glucose co-transporter 2 inhibitors; Diabetic ketoacidosis; Glucagon; Insulin; Type 2 diabetes mellitus

Track Your Manuscript

Share This Page

Media Partners